Cargando…
Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic cha...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680431/ https://www.ncbi.nlm.nih.gov/pubmed/36412596 http://dx.doi.org/10.3390/diseases10040102 |
_version_ | 1784834416170762240 |
---|---|
author | Abdullah, Israa AlMojil, Khaled Shehab, Mohammad |
author_facet | Abdullah, Israa AlMojil, Khaled Shehab, Mohammad |
author_sort | Abdullah, Israa |
collection | PubMed |
description | Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic challenging. Dual target therapy (DTT), combining biologics and/or small molecule drugs, may offer a chance to achieve remission in these cases and improve patients’ quality of life despite the limited evidence regarding this approach. We present a case series of refractory inflammatory bowel disease cases managed with DTT. Seven patients with refractory IBD achieved steroid free, clinical, and endoscopic remission by using DTT. These results support that DTT could be an effective approach in selected patients with refractory IBD or with concomitant extra-intestinal manifestations (EIM). Larger studies, ideally randomized controlled trials, are needed to further support the evidence and confirm the efficacy and safety of DTT for IBD. |
format | Online Article Text |
id | pubmed-9680431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96804312022-11-23 Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease Abdullah, Israa AlMojil, Khaled Shehab, Mohammad Diseases Article Inflammatory bowel disease (IBD) is a chronic autoimmune disease with relapse–remission courses. A number of patients may present with a refractory disease with partial or no response to treatment. Others may present with extra-intestinal manifestations that makes the treatment with one biologic challenging. Dual target therapy (DTT), combining biologics and/or small molecule drugs, may offer a chance to achieve remission in these cases and improve patients’ quality of life despite the limited evidence regarding this approach. We present a case series of refractory inflammatory bowel disease cases managed with DTT. Seven patients with refractory IBD achieved steroid free, clinical, and endoscopic remission by using DTT. These results support that DTT could be an effective approach in selected patients with refractory IBD or with concomitant extra-intestinal manifestations (EIM). Larger studies, ideally randomized controlled trials, are needed to further support the evidence and confirm the efficacy and safety of DTT for IBD. MDPI 2022-11-09 /pmc/articles/PMC9680431/ /pubmed/36412596 http://dx.doi.org/10.3390/diseases10040102 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Abdullah, Israa AlMojil, Khaled Shehab, Mohammad Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title | Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title_full | Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title_fullStr | Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title_full_unstemmed | Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title_short | Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease |
title_sort | effectiveness of dual biologic or small molecule therapy for achieving endoscopic remission in refractory inflammatory bowel disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680431/ https://www.ncbi.nlm.nih.gov/pubmed/36412596 http://dx.doi.org/10.3390/diseases10040102 |
work_keys_str_mv | AT abdullahisraa effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease AT almojilkhaled effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease AT shehabmohammad effectivenessofdualbiologicorsmallmoleculetherapyforachievingendoscopicremissioninrefractoryinflammatoryboweldisease |